Non-invasive brain injury diagnostic device

A device for diagnosing a brain injury in a subject, comprising:

• a probe, said probe comprises a porous matrix;
• and
• an indicator formulation disposed in and/or on said porous matrix and comprises at least one glycan-based biomarker binding reagent for selectively binding to a glycan-based biomarker in a sample, and a first visually detectable label;
• wherein:
• at least one of said glycan-based biomarker binding reagent and/or said first visually detectable label is immobilized in and/or on a detection zone in said porous matrix;
• said glycan-based biomarker is indicative of brain injury;
• said first visually detectable label develops a color and becomes visible upon a binding event of said glycan-based biomarker to said glycan-based biomarker binding reagent;
• and
• said binding event is effected by contacting said sample with said probe.

A device for diagnosing a brain injury in a subject, comprising:

• a flat round probe, said probe comprises a porous matrix;
• an indicator formulation disposed in and/or on a detection zone in said porous matrix and comprises at least one glycan-based biomarker binding reagent for selectively binding to a glycan-based biomarker in a sample, and a first visually detectable label;
• a control formulation disposed in and/or on a control zone in said porous matrix and comprises a control binding reagent and a second visually detectable label;
• and
• a handle in communication with said probe,
• wherein:
• said glycan-based biomarker is indicative of brain injury;
• at least one of said glycan-based biomarker binding reagent and/or said first visually detectable label is immobilized in and/or on said detection zone;
• said first visually detectable label develops a color and becomes visible upon a binding event of said glycan-based biomarker to said glycan-based biomarker binding reagent;
• said control binding reagent binds at least one of said glycan-based biomarker binding reagent, a glycan and any complex thereof;
• said control binding reagent and/or said second visually detectable label is immobilized in and/or on said control zone;
• said second visually detectable label becomes visible upon a binding event of said control binding reagent to said glycan-based biomarker binding reagent, said glycan and/or said complex thereof;
• and
• said binding event is effected by contacting said sample with said probe.